Tharimmune Shares Promising TH104 Data at Liver Meeting

Tharimmune Inc., a clinical-stage biotechnology company, recently unveiled Phase 1 clinical data for its lead therapeutic, TH104, at the American Association for the Study of Liver Disease 2024 meeting in San Diego. The study focused on patients with chronic liver disease (CLD) and showed significant correlation between blood levels and symptom relief, with no unexpected adverse events observed.

The trial explored TH104's safety and efficacy in two cohorts categorized by Child-Pugh scores, assessing pruritus intensity using the Worst-Itch Numerical Rating Scale (WI-NRS). Notably, after administering a single low dose, participants experienced a notable reduction in WI-NRS scores, indicating relief from itch symptoms.

Tharimmune plans to advance to Phase 2 trials, targeting chronic pruritus in primary biliary cholangitis patients, with expectations to release preliminary data in 2025. CEO Randy Milby emphasized ongoing collaboration with U.S. and EU regulatory authorities for future development.